Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases.
We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the VIB Gent, the University of Michigan, and more recently the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science.
Our most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis that is Phase II ready. Molecure expects to start a Phase II trial in patients with sarcoidosis in 2023.
Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is at the stage of Phase I clinical development.
Our Business Model
- Our business model is based on successfully building a pipeline of small molecule drug candidates both internally and via selective in-licensing deals. We then plan to partner with global pharmaceutical and biotechnology companies for further clinical development and/or commercialization. The preferred stage of development for out-licensing is early clinical Proof of Concept.
- Our partnerships with top global academic research institutes, combined with our exceptional capabilities in medicinal chemistry and translational science, have allowed the company to access the untapped, first/best-in-class novel biology targets – both proteins and mRNA – needed to generate a pipeline of first-in-class drug candidates.
- Our approach to drug discovery is based on bold target selection, both proteins and mRNA, traditionally undrugged by small molecules, with limited competition. Drug candidates developed using this approach have attractive commercial potential and will address disease areas with significant unmet medical needs.
- Our entrepreneurial/risk taking approach allows us to successfully work on challenging, high reward targets given our preferential access to the highly regarded and rapidly growing pool of Polish top life science talent.
|March 18-20, 2024
|BIO Europe, Barcelona
|March 29, 2024
|Publication of the Company's Annual Reports for the year 2023
|April 30, 2024
|Publication of the Company’s 1st quarter 2024 report
|June 3-6, 2024
|BIO International Convention, Boston
|September 27, 2024
|Publication of the Company’s half year 2024 report
|October 31, 2024
|Publication of the Company’s 3rd quarter 2024 report
|November 4-6, 2024
|BIO Europe, Stockholm
ON the WSE FROM
April 19, 2018
MARKET / QUOTATION SEGMENT
WSE / Parallel
NUMBER OF SHARES ISSUED
16 836 000